Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on December 3rd, 2022%
The data show falling numbers of young men and women in sub-Saharan Africa with new HIV infections since 2010, but the percentage of infected women and girls also rising over that time. . . . → Read More: Infographic – Higher HIV Burden for Women, Girls in Africa
By Alan, on December 2nd, 2022%
Results of a clinical trial show a nasal swab dispensing an opioid antidote transfers more of the antidote into the blood stream than syringe injections or nasal sprays. . . . → Read More: Trial Shows Fast-Absorbing Opioid Overdose Nasal Swab
By Alan, on November 19th, 2022%
More than 133 million people have diabetes, nearly one-third of the world’s total, yet almost half of the world’s diabetes drug sales volume is in the U.S. . . . → Read More: Infographic – U.S. Dominates Diabetes Drug Sales
By Alan, on November 18th, 2022%
A company building a therapy and technology network for improving access to mental health providers is raising $15 million in its first venture round. . . . → Read More: Mental Health Therapy, Tech Network Gains Early Funds
By Alan, on November 4th, 2022%
Researchers at University of Houston are creating a system aided by algorithms for primary care physicians to better identify people at risk for complications from diabetes. . . . → Read More: AI-Aided System to Identify Diabetes Complication Risks
By Alan, on November 2nd, 2022%
A vaccine designed from engineered live viruses and taken as nose drops to prevent respiratory syncytial virus received a Food and Drug Administration fast-track designation. . . . → Read More: RSV Nose Drops Vaccine Gets FDA Fast Track Tag
By Alan, on October 26th, 2022%
Results from a clinical trial show an experimental one-time antibody therapy, even at low doses, lowers levels of HIV virus in people living with the disease. . . . → Read More: Trial Shows Antibody Neutralizes, Reduces HIV Virus
By Alan, on October 21st, 2022%
A developer of faster infection diagnostics is receiving another $8.2 million from an international group supporting solutions to antibiotic resistant microbes. . . . → Read More: New Funds Awarded for Rapid Infection Diagnostics
By Alan, on October 6th, 2022%
A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea. . . . → Read More: Nasal Spray Vaccines Get CEPI, NIH Funding
By Alan, on October 4th, 2022%
A vaccine grown in genetically-altered algae, designed as a nasal-spray and edible drug, is shown to protect lab mice against parasite infections causing malaria. . . . → Read More: Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|